



Supplementary U.S. Dollar Financial Information For the six months ended 31 December 2003

Ansell Limited and its Controlled Entities

ACN 004 085 330

The following unaudited US dollar financial information is supplementary to the Company's Appendix 4D Half Year Report for the six months ended 31 December 2003 filed with the ASX on 11 February 2004. It is provided as additional information for the Company's shareholders. This financial information does not form part of the Company's financial statements that are required to be prepared under the Corporations Act 2001, Australian Accounting Standards and the ASX listing rules.

This financial information has been derived from the Company's Appendix 4D.

Translation of amounts from Australian dollars to US dollars in the Statement of Financial Performance, Statement of Cash Flows and Operating Revenue and Operating Result within the Industry Segments have been made at the average of the 10a.m. mid buy/sell rate for Australian dollars as quoted by Reuters on the last working day of each month for the 7 month period June 2003 to December 2003.

Translation of amounts from Australian dollars to US dollars in the Statement of Financial Position and Assets Employed and Liabilities within the Industry Segments have been made at the 10a.m. mid buy/sell rate for Australian dollars as quoted by Reuters, on Wednesday 31 December 2003, at US\$0.75005 = A\$1 (30 June 2003 US\$0.66675 = A\$1).

Unaudited U.S. Dollar Financial Information

Statement of Financial Performance

of Ansell Limited and its Controlled Entities for the six months ended 31 December 2003

	2003 US\$m	2002 US\$m
Revenue		
Sales	383.4	363.1
Other revenue	4.3	8.6
Total revenue	387.7	371.7
Expenses		
Cost of good sold	227.8	235.6
Selling, distribution and administration	102.1	88.0
Depreciation and amortisation	16.3	16.2
Write-down of assets	0.7	-
Total expenses, excluding borrowing costs	346.9	339.8
Borrowing costs	10.2	11.2
Share of net gain of associates' and joint venture entities	-	0.2
Profit from ordinary activities before income tax expense	30.6	20.9
Income tax expense attributable to ordinary activities	6.3	9.4
Net profit from ordinary activities after income tax expense	24.3	11.5
Outside equity interests in net profit after income tax	0.8	0.7
Net profit after income tax attributable to Ansell Limited shareholders	23.5	10.8
	cents	cents
Earnings per share is based on Net Profit/(Loss) after income tax attributable to Ansell Limited shareholders		
Basic earnings per share	12.7	5.8
Diluted earnings per share	12.6	5.7

Unaudited U.S. Dollar Financial Information

Statement of Financial Position

of Ansell Limited and its Controlled Entities

	31 December 2003	30 June 2003
	US\$m	US\$m
Current Assets		
Cash	195.5	190.7
Cash - restricted deposits	8.5	9.2
Receivables ^(b)	170.0	175.0
Inventories	141.3	125.3
Prepayments	10.4	7.2
Total Current Assets	525.7	507.4
Non-Current Assets		
Receivables ^(b)	46.4	38.0
Other investments ^(a)	105.2	94.3
Other property, plant and equipment	166.3	175.3
Intangible assets	210.6	216.4
Tax assets	19.7	21.3
Total Non-Current assets	548.2	545.3
Total Assets	1,073.9	1,052.7
Current Liabilities		
Payables	122.9	103.0
Interest-bearing liabilities	77.7	101.2
Provisions	33.1	38.3
Current tax liabilities	1.3	2.1
Other	-	0.7
Total Current Liabilities	235.0	245.3
Non-Current Liabilities		
Payables	2.2	2.1
Interest-bearing liabilities	223.1	213.4
Provisions	16.2	14.5
Deferred tax liabilities	14.2	14.3
Total Non-Current Liabilities	255.7	244.3
Total Liabilities	490.7	489.6
Net Assets	583.2	563.1
Equity		
Contributed equity	1,060.1	965.7
Reserves	(235.1)	(179.3)
Accumulated losses	(248.9)	(230.5)
Total Equity Attributable to Ansell Limited Shareholders	576.1	555.9
Outside equity interests	7.1	7.2
Total Equity	583.2	563.1

(a) Includes investment in South Pacific Tyres Partnership and South Pacific Tyres N.Z. Ltd of US\$ 103.6 (June 2003 US\$ 92.2m).

(b) Includes interest bearing loans to South Pacific Tyres Partnership of US\$ 45.7m (June 2003 US\$ 41.8m).

Unaudited U.S. Dollar Financial Information

Statement of Cash Flows

of Ansell Limited and its Controlled Entities for the six months ended 31 December 2003

	2003 US\$m	2002 US\$m
Cash flows Related to Operating Activities		
Receipts from customers (excluding non recurring and Accufix Research Institute)	408.6	386.0
Payments to suppliers and employees (excluding non recurring and Accufix Research Institute)	(335.9)	(339.2)
Net receipts from customers (excluding non recurring and Accufix Research Institute)	72.7	46.8
Income taxes paid	(6.9)	(0.9)
Dividends received	-	1.4
Net cash provided by operating activities (excluding non recurring and Accufix Research Institute)	65.8	47.3
Non recurring payments to suppliers and employees	(3.6)	(8.2)
Payments to suppliers and employees net of customer receipts (Accufix Research Institute)	(1.0)	(1.4)
Net Cash Provided by Operating Activities	61.2	37.7
Cash Flows Related to Investing Activities		
Payments for businesses, net of cash acquired	-	-
Payments for property, plant and equipment	(3.8)	(4.2)
Proceeds from sale of businesses, net of cash disposed	-	-
Proceeds from sale of plant and equipment in the ordinary course of business	0.3	0.4
Loans repaid	-	0.3
Proceeds from sale of other investments	-	4.5
Net Cash Provided by Investing Activities	(3.5)	1.0
Cash Flows Related to Financing Activities		
Proceeds from borrowings	0.6	4.3
Repayments of borrowings	(23.3)	(39.3)
Net repayments of borrowings	(22.7)	(35.0)
Proceeds from issues of shares	0.6	0.4
Payments for share buy-back	(25.5)	-
Dividends paid	(14.1)	(0.9)
Interest received	2.9	2.2
Interest and borrowing costs paid	(10.6)	(11.3)
Net Cash Used in Financing Activities	(69.4)	(44.6)
Net (Decrease)/Increase in Cash Held	(11.7)	(5.9)
Cash at the beginning of the financial period	198.4	148.6
Effects of exchange rate changes on the balances of cash held in foreign currencies at the beginning of the financial period	14.9	0.9
Cash at the End of the Financial Period	201.6	143.6

Unaudited U.S. Dollar Financial Information

Industry Segments

of Ansell Limited and its Controlled Entities for the six months ended 31 December 2003

	Operating Revenue		Operating Result	
	December		December	
	2003	2002	2003	2002
	US\$m	US\$m	US\$m	US\$m
INDUSTRY				
Ansell Healthcare				
Occupational Healthcare	183.1	177.4	22.7	15.0
Professional Healthcare	133.4	124.7	15.0	15.9
Consumer Healthcare	66.9	61.0	12.4	12.2
Ansell Healthcare	383.4	363.1	50.1	43.1
Unallocated Items	4.3	8.6	(5.4)	(6.7)
Operating EBITA			44.7	36.4
NON RECURRING				
Discontinued Businesses				
Net gain on sale of interests in Associated Companies				3.1
Other			5.5	
Rationalisation/Restructuring				
Ansell Healthcare			(5.3)	
Other				(3.1)
Write-down of assets				
Other			(0.7)	
EBITA			44.2	36.4
Goodwill amortisation			(7.6)	(7.3)
Earnings before Net Interest and Tax (EBIT)			36.6	29.1
Borrowing Costs net of Interest Revenue			(6.0)	(8.2)
Operating Profit before Tax			30.6	20.9
Tax			(6.3)	(9.4)
Outside Equity Interests			(0.8)	(0.7)
Total Consolidated	387.7	371.7	23.5	10.8
REGIONS				
Asia Pacific	59.0	48.1	13.8	10.3
Americas	191.8	193.0	21.1	26.1
Europe	132.6	122.0	15.2	6.7
	383.4	363.1	50.1	43.1

	Assets Employed		Liabilities	
	December	June	December	June
	2003	2003	2003	2003
	US\$m	US\$m	US\$m	US\$m
INDUSTRY				
Ansell Healthcare				
Occupational Healthcare	197.2	189.6	65.8	60.0
Professional Healthcare	209.9	207.2	52.1	42.6
Consumer Healthcare	75.4	74.3	25.7	26.3
Total Ansell Healthcare	482.5	471.1	143.6	128.9
Unallocated Items	11.5	16.6	330.8	341.8
Discontinued Businesses	165.3	148.7	16.3	18.9
Goodwill and Brand names	210.6	216.4		
Cash	204.0	199.9		
Total Consolidated	1,073.9	1,052.7	490.7	489.6
REGIONS				
Asia Pacific	184.6	179.7	47.8	52.4
Americas	173.0	170.8	62.8	57.8
Europe	124.9	120.6	33.0	18.7
	482.5	471.1	143.6	128.9

Unaudited U.S. Dollar Financial Information

Notes to the Industry Segments Report

(a) Unallocated Revenue and Costs

Represents costs of Statutory Head Office, part of the costs of Ansell Healthcare's Corporate Head Office and non-sales revenue.

(b) Cash

Cash also includes Accufix Pacing Leads restricted deposits.

(c) Inter-Segment Transactions

Significant inter-segment sales were made by Asia Pacific - US\$75.1 million (2002 - US\$69.8 million) and America - US\$66.2 million (2002 - US\$59.9 million). Inter-segment sales are predominantly made at the same prices as sales to major customers. Operating revenue is shown net of inter-segment values. Accordingly, the Operating revenues shown in each segment reflect only the external sales made by that segment.

(d) Industry Segments

The consolidated entity comprises the following main business segments:

Occupational Healthcare - manufacture and sale of occupational health and safety gloves.

Professional Healthcare - manufacture and sale of medical, surgical and examination gloves for hand barrier protection and infection control.

Consumer Healthcare - manufacture and sale of condoms, household gloves and other personal products.

Discontinued Businesses - represents former Industry Segment businesses which have been sold or abandoned.

(e) Regions

The allocation of Operating Revenue and Operating Results reflect the geographical regions in which the products are sold to external customers. Assets Employed are allocated to the geographical regions in which the assets are located.

Asia Pacific - manufacturing facilities in 4 countries and sales.

Americas - manufacturing facilities in USA and Mexico and significant sales activity.

Europe - principally a sales region with one manufacturing facility in the UK.

	2003 December US\$m	2002 December US\$m
(f) Segment Capital Expenditure		
Occupational Healthcare	1.2	0.9
Professional Healthcare	1.6	3.0
Consumer Healthcare	1.0	0.3
Discontinued Businesses	-	-
(g) Region Capital Expenditure		
Asia Pacific	2.5	3.3
Americas	1.0	0.6
Europe	0.3	0.3
(h) Segment Depreciation		
Occupational Healthcare	2.9	3.1
Professional Healthcare	3.9	4.4
Consumer Healthcare	1.9	1.3
Discontinued Businesses	-	-
(i) Segment Other Non Cash Expenses (excluding Provision for Rationalisation and Write-down of Assets separately disclosed)		
Occupational Healthcare	2.5	2.2
Professional Healthcare	0.4	0.4
Consumer Healthcare	1.3	1.5
Discontinued Businesses	-	-